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Abstract
Introduction: The interest in patient demographics and disease management has increased in the past years due
to their utility in developing measures that allow healthcare providers to reflect disease complexity.
Objective: To revise the current status of spinal muscular atrophy in the region of Catalonia, and to validate the
utility of the database for this aim.
Methods: Five hundred twenty-four patients diagnosed with a spinal muscular atrophy were identified in the
region of Catalonia via the novel program of data analysis for research and innovation in health (PADRIS). Patient
records included in the analysis corresponded to primary care, hospital, emergency room, extended care and
mental health admissions between 2007 and 2017.
Results: 58.02% of patients with a SMA diagnosis were males while 40.84% were females. Average age of diagnosis
was 38.31 ± 24.49 years ±SD. Significantly lower was the age of diagnosis of spinal muscular atrophy type I, 1.81 ±
3.01 years. An average of 22 patients died per year during the study period, with a mean decease age of 62.96 ±
25.41 years. Patients were generally attended in hospitals, and the use of healthcare resources was focused on
resolving respiratory issues and scoliosis. The highest ratio of admissions per patient was registered in those aged 0
to 4 years. Patients presented a higher risk than the general population and a higher frequency of multimorbidites.
Conclusions: Patients exhibited similar characteristics to prior European studies. Multiple admissions in younger
patients, mostly due to respiratory issues, have a central role in increasing medical costs of SMA. Equally, the higher
risk of patients and increased number of multimorbidity groups translate in an elevated number of admissions in
health centres and ER, deriving in higher expenses.
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Introduction
Spinal muscular atrophy (SMA) describes a group of her-
editary and recessive neuromuscular disorders caused by
the degeneration of anterior horn cells resulting in muscle
atrophy and weakness [1]. Contrarily, progressive SMA re-
fers to a non-hereditary condition [2]. Distinct SMA types
are characterized by different degrees of motor function
and age of onset. SMA-I or Werdnig-Hoffmann syn-
drome, is diagnosed during the first 6 months of life, and
causes severe development limitations. SMA-II has its on-
set between 7 and 18months of age, before the child is
able to walk. SMA-III or Kugelberg-Welander syndrome
is divided in two subtypes; type IIIa is diagnosed in chil-
dren of 2 to 3 years of age, who will have orthopaedic is-
sues; and type IIIb appears between 3 years of age and late
adolescence. These patients have a normal motor develop-
ment [3, 4]. SMA-IV and zero have been described a pos-
teriori and refer to SMA with an adult onset and the
disease affecting children in the first weeks of life respect-
ively [3, 5].
Considering all disease manifestations, the paediatric
population remains the most affected by this disorder.
Additionally, SMA-0 and SMA-I present the most severe
forms of the condition, which determines the import-
ance of paediatric care [5]. SMA is estimated to affect
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around 1 in 10,000 live births [6], with irregularities
among regions and ethnic groups [7], thus the import-
ance to evaluate disease demographics at a regional level.
The analysis of patient demographics has been proven
useful to determine the specific needs of patients and
physicians in terms of use of healthcare resources, in
order to develop measures that allow reflexing disease
complexity [8]. To facilitate such analyses, healthcare
providers collect detailed information on healthcare
usage. In Spain, the Catalan agency for quality and
sanitary evaluation (AQuAS) recently implemented a
new program to register this data, the program of data
analysis for research and innovation in health (PADRIS)
[9]. Consequently, the aim of this study was to develop a
retrospective multicentre analysis via the records regis-
tered in PADRIS to scrutinise SMA patients’ demo-
graphics and disease management in Catalonia between
2007 and 2017. A secondary objective of the study was
to validate the utility of PADRIS records prior to the
program’s full operation.
Methods
The study analysed records of all patients with a diagno-
sis of SMA in the region of Catalonia (7.5 million inhab-
itants) between 2007 and 2017. Data was obtained from
project PADRIS, managed by AQuAS, via ethics com-
mittee approval. The database includes detailed informa-
tion of healthcare usage, comprising primary care
centres, hospitals (inpatient and outpatient care), ex-
tended care facilities and mental health centres. Records
in the database are validated automatically via the evalu-
ation of data consistency. Patient diagnoses and proce-
dures were determined by means of the 9th revision of
the International Statistical Classification of Diseases
and Related Health Problems (ICD-9). When necessary,
the extraction of single-patient information was carried
out by eliminating repeated records corresponding to
separated admissions, relying on the first admission as
the index event.
The classification assigns patients an adjusted morbid-
ity group (GMA), according to the number of systems
they have affected by chronic diseases, and into 5 levels
of complexity or risk. As it increases, GMA level corre-
lates with a higher number of healthcare admissions of
these patients and major pharmaceutical costs [10].
Data presentation is mainly descriptive. All statistical
analyses were performed using Microsoft Excel© Profes-




The ICD9 codes analysed represented SMA types I
and II individually, and types II and IV together in
the same cluster. Progressive SMA was considered in-
dependently, and a separate group designated the
cases where SMA type was not specified (Table 1).
The first set of analyses examined patient records cor-
responding to 524 patients, most of them diagnosed with
a progressive SMA. As for other SMA types, clear trends
could not be detected due to the database characteris-
tics. A clear sex bias was observed for most SMA types,
with a proportion 60 to 40% male-female. SMA-II did
not exhibit this pattern. Patients with no specified sex
represented between 1 and 5% of the total (Table 2).
Patients’ first admission with a SMA diagnosis was
examined to estimate average age of diagnosis. The test
revealed an average age of diagnosis of 38.31 ± 24.49
years. Differences between males and females were not
evident for this parameter.
The database made available data on patients deceased
during the study period, which allowed a rough estima-
tion of mortality and an analysis of patients age at time
of death (Table 3). Likewise, a qualitative analysis of the
time elapsed between diagnosis and decease was consid-
ered relevant. Patients with SMA-I died 2 months to 3
years after diagnosis and patients with SMA-III died on
average 6 months after diagnosis. Longer times elapsed
for SMA-II, SMA-IV and progressive SMA, averaging
between 4 and 5 years. An average of 22 patients died
per year during the study period.
The program assigns patients a GMA, according to
the number of systems they have affected by chronic
diseases, and are classified into 5 levels of complexity.
The year 2016 (last available data) the population in
this study was comprised by 71.26% of patients with
4 or more systems affected by a chronic condition,
17.53% of patients with 2 or 3 systems affected by a
chronic condition, 6.32% of patients with an active
neoplasm and 4.89% patients with 1 system affected
by a chronic condition. As part of GMA calculation,
patients were classified into 5 complexity or risk
levels based of the general population as characterised
in Fig. 1. The majority of patients with a SMA diag-
nosis would be represented in the very high risk level
(27%) via the GMA population-based health risk
stratification tool.
Table 1 SMA types claimed by ICD9 codes
Disease classification ICD9 code
SMA-I. Werdnig-Hoffmann syndrome 335.0
SMA-III. Kugelberg-Welander syndrome 335.11
SMA-II and SMA-IV 335.19
Progressive SMA and Duchenne-Aran 335.21
Unspecified SMA 335.10
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Disease management
The classification of patient records permitted the ana-
lysis of separate episodes or independent admissions.
The evaluation of disease management was based on a
calculation of the services that attended the patients, the
motivation of such admissions, an analysis of medical
procedures and patient’s destination after discharge.
Most admissions were registered in primary healthcare
centres, 36,724. Significantly smaller was the number of
hospitalisations and outpatient consultations, 2518. A
similar number of admissions corresponded to emer-
gency room (ER) visits, 2836. Extended care facilities
registered 659 admissions, and 13 records were obtained
from mental care consultations. In the majority of ad-
missions origin was indicated. 49.70% were scheduled
admissions and 49.60% were urgent, the rest were
unspecified. Considering all SMA-related admissions,
the total number of admissions per patient was slightly
superior in younger individuals. In patients aged 0 to 4
years, 3.0 admissions per patient were registered; in
those aged 5 to 9 years 2.1 admissions were registered; in
children aged 10 to 14 this parameter measured 1.7; fi-
nally, in patients older than 20 years of age it remained
stable around the 1.2 admissions per patient.
Hospitalisation time averaged 8 days, excluding the
stays in extended care facilities. As for patients’ destin-
ation after discharge, it was generally their residence,
followed by transfers to extended care facilities.
On admission, patients were classified and diagnosed with
a variety of symptoms and conditions, commonly with a dir-
ect link to SMA. Such conditions, excluding SMA, are listed
in Table 4. Hospital admissions due to respiratory issues
were significant in all groups; certain conditions as asthma or
scoliosis were important hospitalisation motives in patients
with infantile onsets of SMA. SMA-II and IV and progressive
SMA, patients were often treated for diabetes mellitus type II
and hypertension; equally, pressure ulcers appeared mostly
in patients with progressive SMA. In order to determine the
medical procedures chosen for these patients, admissions dir-
ectly linked to SMA were selected. To this aim, the analysis
included admissions with SMA diagnoses, those due to re-
spiratory symptoms and other manifestations as dysphagia,
anaemia, nutritional deficiencies and gastrointestinal issues.
The aforementioned admissions took place mostly into
hospitals (inpatient and outpatient care) and ER, and the
most representative procedures were associated to re-
spiratory difficulties (Table 5). Nursing care procedures
were predominant in primary healthcare centres,
focusing on sanitary education regarding the disease, the
prescribed medication, diet or exercise, and the adminis-
tration of intramuscular medication.
Discussion
Interest in disease management data and patient charac-
teristics has drastically increased in the past years. The
analysis of patient records has been effective to orientate
healthcare providers and governments and allow the ap-
plication of measures that translate disease complexity
[11]. Herein, the PADRIS program allowed the assess-
ment of SMA current status in the region of Catalonia
in consideration of patient demographics and disease
management. The 524 patients included in the study
were diagnosed with SMA between the years 2007 and
2017. Findings regarding patients’ sex distribution are
consistent with those in prior studies. SMA is generally
presented in higher frequencies in males, often near the
60% [12]. Similar observations were made in previous
studies, in which patients’ sex seemed to play a role in
Table 2 Characteristics of the population of study
Patient number % of patients % of male patients % of female patients Patients age ± SD
Total 524 58.02 40.84 38.31 ± 24.49
SMA-I 38 6.34 60.53 36.84 1.81 ± 3.01
SMA-III 84 14.02 51.19 45.24 25.11 ± 25.87
SMA-II and SMA-IV 62 10.35 61.29 33.87 58.25 ± 20.63
Progressive SMA 229 38.23 56.77 38.86 58.32 ± 23.61
Unspecified SMA 111 18.53 59.46 38.74 48.04 ± 27.00
Table 3 Patients deceased during the studied period
Patient number % of patients % of male patients % of female patients Patients age ± SD
Total 226 50.00 32.24 62.96 ± 25.41
SMA-I 17 44.74 47.83 42.86 0.50 ± 0.91
SMA-III 15 17.86 71.31 10.53 63.91 ± 24.33
SMA-II and SMA-IV 26 41.94 44.74 38.10 71.73 ± 13.26
Progressive SMA 110 48.03 53.08 40.45 67.25 ± 20.69
Unspecified SMA 58 52.25 68.18 34.88 64.40 ± 22.76
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disease severity [13, 14], although to this moment the
mechanism of modulation has not been fully under-
stood. A previous study in Spain suggested that it was
the acute form of this disorder (SMA-I) the only variant
affecting mostly females [15]. Most of the patients in the
study were diagnosed with a progressive SMA, explain-
able by the lower specificity of its ICD9 classification.
Given the characteristics of the database, data from this
study cannot be used to infer disease prevalence, which
poses as one of the limitations of database retrospective
analyses.
Patients’ average age of diagnosis displayed reasonable
variations among SMA types. SMA-I was diagnosed on
average at 1.81 years, which is slightly elevated [5]. Like-
wise, average age of diagnosis of SMA-III, with a typical
juvenile onset, is 25.11 years. Inevitably, delays due to
Fig. 1 GMA health complexity levels. Risk 1 -green- low risk to 5 -red- very high risk in A) general population [10] and B) patients with SMA in 2016
Table 4 Number of admissions for other causes per SMA type
Diagnoses SMA-I SMA-III SMA-II and IV Progressive SMA
Abdominal pain 6 29 49 80
Acute bronchitis 43 70 19 2
Acute respiratory failure 29 15 7 31
Anxiety 11 25 27 120
Asthma, unspecified 106 262 76 54
Breath abnormality 39 74 4 37
Chronic bronchitis 39 45 33 198
Chronic respiratory failure 8 13 2 31
Diabetes mellitus type II 37 254 526 2295
Disuse muscular atrophy 33 79 20 46
Infantile cerebral palsy, unspecified 65 68 0 32
Lumbar pain 1 8 12 58
Malaise and fatigue 1 2 14 57
Obesity 2 52 11 112
Pulmonary collapse 27 41 1 3
Pressure ulcer 10 15 96 258
Quadriplegia 7 8 25 26
Scoliosis 19 49 5 19
Supplementary oxygen dependency 7 17 0 10
Unspecified essential hypertension 83 284 590 1368
Patient number 38 84 62 229
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miscoding cannot be ruled out. Still, the relevance of
paediatric onsets appears tangible in the number of ad-
missions registered per patient, superior in younger pa-
tients. This is not surprising given the gravity of SMA-0
and SMA-1, the variants with the earliest onsets [5].
Equally, age of decease generally correlates with previous
findings. Patients with SMA-I typically die within the
first 2 years of life [5], while patients affected with SMA-
II, SMA-III and SMA-IV tend to die during their adult
life. As for the time elapsed between diagnosis and de-
cease, a relative small percentage of patients was avail-
able for consideration, allowing misconceptions.
However, it is interesting to remark the average survival
of patients with a progressive SMA, which correlates
with the 4.6 years median survival displayed in a previ-
ous disease course study [2].
Novel information was provided by means of the GMA
health risk stratification system. A rough assessment of
patients’ relative risk provides a tool to refine disease eval-
uations and predict results in the use of health resources
[10]. Analyses prove that as many as 71.26% of patients
with SMA are affected by 4 or more chronic diseases in
distinct organs, a percentage that measured 14.9% in the
general population, which is likely to translate into a more
intensive use of healthcare resources [10]. The study of
multimorbidity groups will be crucial to evaluate patients’
healthcare needs in an effort to promote preventive care,
taking into consideration that direct medical costs can ac-
count for at least 30% of all costs associated with a patient
with SMA [16, 17].
In this context, and in terms of disease management,
current available information reflects the predominant
use of SMA patients of primary healthcare, although
most diagnosis and treatment procedures are performed
in specialised healthcare facilities, both in and outpatient
care. The majority of these admissions were related to
respiratory issues derived from the disease, in addition
to any patients with a diagnosis of SMA with respiratory
distress that could contribute to this outcome [18]. Add-
itional chronic conditions as type II diabetes or essential
hypertension registered on admission confirm the weight
of multimorbidity in patients’ use of resources.
Nonetheless, procedures aimed to resolve respiratory
problems made up for the majority of measures. Oxygen
enrichment and mechanical ventilation are crucial when
patients present respiratory muscle weakness and still
are the preferred treatment in such cases [19, 20]. Other
repeated procedures are designed to reduce motor im-
pairment, as the fixation or reconstruction of pelvic
bones, an expected outcome given the recommendation
for intervention in these patients to diminish the conse-
quences of scoliosis, surgery that appears in the highest
percentages in the youngest patients to lose ambulation
capacity [4, 21].
It is plausible that a number of limitations may have
influence in the results obtained. Data recording in the
distinct healthcare sources started at varied time points
between 2007 and 2012, and the restricted use of accur-
ate ICD9 definitions during the first studied years left a
considerable amount of data unspecified. Moreover, the
use of ICD9 for codification in the database limits the
relevance of the results; the lack of specific codes for
SMA-II and SMA-IV impede further result interpret-
ation. Measures were taken to avoid errors derived from
Table 5 Most common procedures in SMA-related admissions
Procedure Hospital admissions ER admissions Total admissions
Antibiotic injection 3165 11 3888
Oxygen enrichment 2328 7 3004
Routine thorax radiography 1935 308 2619
Mechanical ventilation 1963 9 2581
Respiratory medication 1654 88 2231
Electrolyte injection 1388 25 1858
Electrocardiography 1311 150 1640
Arterial blood gas measurement 1105 41 1375
Steroid injection 1018 17 1293
Respiratory exercise 727 0 983
Blood microscopical analysis 298 483 908
Feeding tube 707 0 881
Transesophageal echocardiography 737 0 850
Tracheal intubation 461 0 548
Reconstructive surgery; pelvic bones 316 0 461
Internal fixation; pelvic bones 266 0 382
Darbà Orphanet Journal of Rare Diseases            (2020) 15:8 Page 5 of 6
miscoding; nonetheless the complete avoidance of data
replication cannot be ensured. Presumably, data herein
and further analysis of the database will provide new in-
formation regarding SMA management in the past years,
facilitating the establishment of improved health proto-
cols, moving towards P4 Medicine: Personalized, Pre-
dictive, Preventive and Participatory.
Conclusions
This study uses the newly established database PADRIS
to assess the current status of SMA in the region of
Catalonia. The 524 patients with a diagnose of SMA ex-
hibited few differences with patients in other European
countries. Patients were treated for SMA mainly in hos-
pitals, and the use of healthcare resources was focused
on resolving respiratory issues, and to a lesser extent, to
diminishing the consequences of scoliosis. Patients pre-
sented a higher risk than the general population associ-
ated with an elevated number of admissions in health
centres and ER, in addition to the elevated incidence of
multimorbidities.
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